AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Aliada Therapeutics, a biotechnology firm focused on developing therapies using innovative blood-brain barrier (BBB)-crossing technology aimed at treating complex central nervous system (CNS) diseases. Aliada’s lead investigational asset, ALIA-1758, is…
Walgreens is expanding its virtual healthcare service to enhance access for patients nationwide. As of October 1, Walgreens Virtual Healthcare is now available in 30 states, a significant increase from its initial launch in nine states. This expansion is designed…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940 (mRNA-4157), an individualized neoantigen therapy (INT), combined with KEYTRUDA® (pembrolizumab),…
Biogen Inc. (Nasdaq: BIIB) shared full results from its Phase 2 IGNAZ study on felzartamab, an investigational anti-CD38 monoclonal antibody, for IgA nephropathy (IgAN) treatment. Data revealed significant reductions in proteinuria, kidney function stabilization, and sustained treatment effects over 18…
LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, increasing its total number of CLIA-certified labs in the U.S. to four. This acquisition enhances LabGenomics’ strategic growth and expands its diagnostic services nationwide, particularly in molecular technology. In…
BioHub Maryland, an initiative aimed at accelerating the life sciences sector in the state, officially opened its new biopharmaceutical workforce training center on October 24 at 9808 Medical Center Drive in Rockville. The event featured Maryland Lt. Governor Aruna Miller…
Losing your sight can profoundly impact your life, affecting everything from connections to experiences. Our eyes serve as a window to the world, and when vision is lost, it can be a devastating experience for many individuals. Vision loss is…
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company specializing in targeted therapies for RAS-driven cancers, has announced promising early data on RMC-9805, a selective inhibitor for the RAS(ON) G12D mutation. The preliminary safety and antitumor results for RMC-9805 were…
This study investigates the rise of AI-based drug repurposing and assesses the factors that drive or hinder its adoption. Traditional drug discovery methods have limitations that fuel interest in AI-based approaches, which promise significant advantages in terms of time, efficiency,…
GeneDx’s GUARDIAN Study Reveals Promise of Whole Genome Sequencing for Newborns Recent findings published in the Journal of the American Medical Association (JAMA) underscore the limitations of traditional newborn screening methods while highlighting the potential of advanced genomic technology to…
Havah Therapeutics, a clinical-stage biopharmaceutical company focused on innovative hormonal implant therapies for breast cancer prevention and treatment, has established a Clinical Advisory Board chaired by founder Stephen Birrell, MD, PhD. This board comprises experts in breast cancer biology, endocrine…
AU-007 Showcases Unique IL-2 Class Profile with Promising Efficacy Data Aulos Bioscience, a pioneering company in the field of immuno-oncology, recently presented significant data supporting the dose selection for its lead therapeutic candidate, AU-007, at the 36th EORTC-NCI-AACR Symposium on…